We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

And the term encompasses an entire category of well-known skin conditions. "This (link) is something that we've known about for, honestly, centuries," Gehlhausen says. Hives are an itchy skin rash ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...